Medication
Cefazolin for Injection
DIN 02108127 · Teva Canada Limited Likely a generic
What it is
- Active ingredients
- Cefazolin — 1 g
- Form and routes
- Powder For Solution · Intramuscular, Intravenous
- Schedule
- PRESCRIPTION
- Authorised since
- 1995-12-31
Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.
Products with the same active ingredient
Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.
Watch this medication
Ontario Drug Benefit coverage
As of 31 July 2026Off-formulary interchangeable Part III-B
Ontario has designated this product interchangeable with a brand product, but it is not an ODB benefit — Part III-B, Off-Formulary Interchangeable. Ontario does not pay for it under the benefit list.
It may be funded through the Exceptional Access Program, which needs a patient-specific application from a prescriber and is decided case by case.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
Products Ontario considers interchangeable
As of 31 July 2026Ontario groups these products together at 1g/Vial Inj Pd-Vial Pk and will substitute one for another at a pharmacy counter in Ontario.
- Cefazolin for Injection 02437112Hikma Canada Limited
- Cefazolin for Injection Usp 02308959Sandoz Canada Incorporated
- Cefazolin Sodium for Injection BP 02465469Sterimax Inc
Ontario lists 1 further product in this group that is not currently marketed in Canada. It is not shown.
This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.
Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.
How it is classified
- Anatomical main group
- Anti-infectives for systemic use
- ATC code
- J01DB04
The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of J01DB04, see the WHO ATC/DDD Index.
Recalls and safety alerts
As of 12 August 2026Archived by Health Canada
2 older notices naming this product have been archived. These are a record of what happened, not current warnings.
Cefazolin for Injection (2017-06-03)
Possible match. This notice names “CEFAZOLIN FOR INJECTION”, and 5 authorised products from 2 companies are sold under that name. The notice does not say which of them is affected.
Cefazolin for injection - 1gm and 10gm PWS
Possible match. This notice names “CEFAZOLIN FOR INJECTION”, and 5 authorised products from 2 companies are sold under that name. The notice does not say which of them is affected.
This list may be incomplete. Health Canada’s recalls data carries no DIN, so notices are matched on wording alone. Search Health Canada recalls for Cefazolin for Injection → How RxMonitor matches recalls, and how often it fails
Source: Health Canada — Recalls and Safety Alerts. Data current as of 2026-08-12. Matched on product name, not on DIN — the feed carries none.